1228587-59-4

Basic information

• Product Name: methyl 1-(3-(pyrrolidin-1-ylmethyl)benzylamino)cyclopropanecarboxylate
• Synonyms: methyl 1-(3-(pyrrolidin-1-ylmethyl)benzylamino)cyclopropanecarboxylate
• CAS NO: 1228587-59-4
• Molecular Weight: 288.39
• Mol File: 1228587-59-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl 1-(3-(pyrrolidin-1-ylmethyl)benzylamino)cyclopropanecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 1-(3-(pyrrolidin-1-ylmethyl)benzylamino)cyclopropanecarboxylate(1228587-59-4)
• EPA Substance Registry System: methyl 1-(3-(pyrrolidin-1-ylmethyl)benzylamino)cyclopropanecarboxylate(1228587-59-4)

Safety Data

• Hazardous Substances Data: 1228587-59-4(Hazardous Substances Data)

Upstream product

• 884507-42-0 3-(pyrrolidin-1′-ylmethyl)-benzaldehyde 
• 72784-42-0 methyl 1-aminocyclopropane-1-carboxylate hydrochloride 

Downstream Products

• 1228587-60-7 methyl 1-((6-amino-2-(methylthio)-5-nitropyrimidin-4-yl)(3-(pyrrolidin-1-ylmethyl)benzyl)amino)cyclopropanecarboxylate 
• 1228585-40-7 4-amino-2-n-butoxy-7-(1''',2'''-ethylidene)-8-[3'-(pyrrolidin-1''-ylmethyl)-benzyl]-5,6,7,8-tetrahydropteridine-6-one 
• 1228587-63-0 methyl 1-((6-amino-2-butoxy-5-nitropyrimidin-4-yl)(3-(pyrrolidin-1-ylmethyl)benzyl)amino)cyclopropanecarboxylate 
• 1228587-62-9 methyl 1-((6-amino-2-(methylsulfonyl)-5-nitropyrimidin-4-yl)(3-(pyrrolidin-1-ylmethyl)benzyl)amino)cyclopropanecarboxylate 

Relevant articles and documents

Identification and optimization of pteridinone toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis

Pteridinone-based Toll-like receptor 7 (TLR7) agonists were identified as potent and selective alternatives to the previously reported adenine-based agonists, leading to the discovery of GS-9620. Analogues were optimized for the immunomodulatory activity and selectivity versus other TLRs, based on differential induction of key cytokines including interferon α (IFN-α) and tumor necrosis factor α (TNF-α). In addition, physicochemical properties were adjusted to achieve desirable in vivo pharmacokinetic and pharmacodynamic properties. GS-9620 is currently in clinical evaluation for the treatment of chronic hepatitis B (HBV) infection.